Entera Bio Ltd. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Shareholders held by Entera Bio Ltd. on September 7, 2022. The company is incorporated in Israel and trades on the Nasdaq Capital Market under the symbols ENTX (Ordinary Shares) and ENTXW (Warrants).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders voted on eight proposals. All proposals were approved. Key voting outcomes include:
- Proposal 1: Election of Yonatan Malca to the Board of Directors for a three-year term (11,060,520 For; 47,457 Against).
- Proposals 2-6: Ratification of compensation for former President of R&D Dr. Phillip Schwartz, CMO Dr. Arthur Santora, CEO Miranda J. Toledano, CFO Dana Yaacov-Garbeli, and the Chairman of the Board. These proposals received significant support but faced higher opposition compared to the director election and auditor ratification.
- Proposal 7: Approval to increase the 2018 Equity Incentive Plan by 576,188 shares (8,420,408 For; 2,624,710 Against).
- Proposal 8: Ratification of Kesselman & Kesselman (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2022 (11,061,302 For; 44,611 Against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document confirms that Proposals 2 through 6 also received necessary approvals under Israeli law.
Key Facts for Investor Verification
- Verify the specific compensation terms for executives (CEO, CFO, CMO, former R&D President) detailed in the Definitive Proxy Statement filed on July 29, 2022.
- Confirm the impact of the 576,188 share increase to the Equity Incentive Plan on potential future dilution.
- Review the full Definitive Proxy Statement for details on the rationale behind the compensation packages that received significant "Against" votes.